Compounds > erianin
Page last updated: 2024-11-08

erianin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Erianin: from Dendrobium chrysotoxum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Dendrobium chrysotoxumspecies[no description available]OrchidaceaeA plant family of the order Asparagales. All members of the orchid family have the same bilaterally symmetrical flower structure, with three sepals, but the flowers vary greatly in color and shape.[MeSH]

Cross-References

ID SourceID
PubMed CID356759
CHEMBL ID10557
SCHEMBL ID1535646
MeSH IDM0454373

Synonyms (32)

Synonym
b817373-k388, same as
nsc-613744
nsc613744
b817373-k346
phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]-
2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
CHEMBL10557 ,
2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenol
bdbm50005478
2-methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenol
S9137 ,
FT-0686606
95041-90-0
erianin
UXDFUVFNIAJEGM-UHFFFAOYSA-N
SCHEMBL1535646
dendrobium chrysotoxum
Q-100898
AC-24234
DTXSID40326751
AKOS025401669
7ba ,
3'-hydroxy-3,4,4',5-tetramethoxybibenzyl
BCP07974
EX-A7098
HY-N0517
CS-0009056
mfcd06795132
CCG-267683
A851725
5-(3,4,5-trimethoxyphenethyl)-2-methoxyphenol
AS-78334

Research Excerpts

Overview

Erianin (Eri) is an ideal drug candidate for inhibiting proliferation and inducing apoptosis in the treatment of psoriasis. Erianin is a natural product derived from Dendrobium chrysotoxum, with promising antitumor activity.

ExcerptReferenceRelevance
"Erianin is a natural small molecule dibenzyl compound extracted from Dendrobium officinale or Dendrobium chrysotoxum. "( Erianin suppresses proliferation and migration of cancer cells in a pyruvate carboxylase-dependent manner.
Guo, Y; Hong, J; Huang, X; Jian, T; Jiang, L; Wang, S; Xie, Z; Yang, F, 2022)		3.61
"Erianin (Eri) is an ideal drug candidate for inhibiting proliferation and inducing apoptosis in the treatment of psoriasis."( Erianin-Loaded Photo-Responsive Dendrimer Mesoporous Silica Nanoparticles: Exploration of a Psoriasis Treatment Method.
Chen, W; Liu, Y; Wei, K; Yu, H; Zheng, F, 2022)		2.89
"Erianin is an active dibenzyl compound isolated from Dendrobium officinale and Dendrobium chrysotoxum and there are very few studies on molecular mechanisms and drug targets of erianin. "( Erianin as a Promising Novel Agent in the Treatment of Neuroblastoma: The Anticancer Effects and Underlying Molecular Mechanisms.
Kocoglu, SS; Seçme, M; Sunay, FB, 2023)		3.8
"Erianin is a natural product extracted from Dendrobium, which possesses multiple pharmacological activities, including antioxidative and antitumor activity."( Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.
Chen, Q; Hu, Y; Song, Z; Yang, L; Zhou, G, 2020)		2.72
"Erianin is a representative index component for the quality control of the D."( Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Jin, CH; Jin, HL; Jin, X; Li, MY; Ma, J; Piao, LX; Ri, M; Wang, JY; Xing, Y; Xu, GH; Yang, A; Zhang, ZH; Zuo, HX, 2021)		2.79
"Erianin is a small chemical compound extracted from Dendrobium chrysotoxum and has excellent antineoplastic effects against a variety of cancers. "( Ecust004 Suppresses Breast Cancer Cell Growth, Invasion, and Migration via EMT Regulation.
Hu, X; Huang, J; Huang, L; Liang, Y; Liu, Z; Nie, H; Sun, L; Wu, F, 2021)		2.06
"Erianin is a natural product isolated from Dendrobium chrysotoxum Lindl."( Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
Cao, Y; Liu, J; Su, C; Zhang, P, 2017)		2.62
"Erianin is a natural product derived from Dendrobium chrysotoxum, with promising antitumor activity."( Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells.
Chang, Z; Fan, Y; Gong, Y; Liu, L; Wang, Z; Wu, D, )		3.02

Effects

Erianin has broad-spectrum antitumor effects, and its tumor-suppressive effects have been confirmed in the study of various diseases. Erianin inhibits tumor activity by suppressing the expression of integrins.

ExcerptReferenceRelevance
"Erianin has been reported to inhibit tumor activity by suppressing the expression of integrins. "( Erianin Controls Collagen-Mediated Retinal Angiogenesis via the RhoA/ROCK1 Signaling Pathway Induced by the alpha2/beta1 Integrin-Collagen Interaction.
Li, X; Liu, X; Ma, J; Shen, H; Xing, Y; Zeng, L, 2022)		3.61
"ERIANIN has broad-spectrum antitumor effects, and its tumor-suppressive effects have been confirmed in the study of various diseases, such as precancerous lesions of the stomach, gastric cancer, liver cancer, lung cancer, prostate cancer, bladder cancer, breast cancer, cervical cancer, osteosarcoma, colorectal cancer, leukaemia, nasopharyngeal cancer and melanoma through the multiple signaling pathways."( The roles of ERIANIN in tumor and innate immunity and its' perspectives in immunotherapy.
Gao, M; Hao, J; Liu, R; Mei, H; Qiu, M; Song, T; Wang, H; Yang, Z; Zhao, K; Zou, D, 2023)		2

Actions

Erianin could cause cell cycle arrest at the G2/M phase. Expression of p21 and p27 were up-regulated, while expressions of CDK1 and Cyclin B1 were down-regulated. Erianin may abolish the activation of the PI3K/Akt pathway.

ExcerptReferenceRelevance
"Erianin could cause cell cycle arrest at the G2/M phase, and the expressions of p21 and p27 were up-regulated, while the expressions of CDK1 and Cyclin B1 were down-regulated."( Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway.
Cai, Z; Fang, R; Shao, J; Xu, Y, 2021)		2.79
"Erianin can inhibit the proliferation of TNBC cells and induce cell cycle arrest and apoptosis, which may ascribe to the abolish the activation of the PI3K/Akt pathway."( Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway.
Cai, Z; Fang, R; Shao, J; Xu, Y, 2021)		3.51

Treatment

ExcerptReferenceRelevance
"Treatment with erianin induced G2/M-phase arrest, apoptosis, and autophagy in OS cells."( Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo.
Cai, Z; Hua, Y; Li, S; Sun, W; Wang, H; Wang, Z; Xu, J; Yin, F; Zhang, T; Zhou, Z; Zuo, D, 2016)		2.22

Pharmacokinetics

ExcerptReferenceRelevance
"The purpose of the present study was to examine the pharmacokinetic characteristics of erianin (2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)-ethyl]-phenol, CAS 95041-90-0), a nature product extracted from Dendrobium chrysotoxum, having notable antitumour activity, after intravenous injection of erianin fat emulsion to beagle dogs."( Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of erianin for intravenous injection in dogs.
Hong, M; Ma, R; Sheng, L; Yang, B; Zhou, H, 2009)		0.8

Bioavailability

ExcerptReferenceRelevance
" However, the low solubility in water, rapid metabolism and elimination from the body lead to poor bioavailability of Erianin, and greatly hinder its clinical application."( Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification.
Li, M; Liu, K; Ma, L; Zhang, Y, 2023)		1.38

Dosage Studied

ExcerptRelevanceReference
"Ecust004 treatment decreased the growth and proliferation of MDA-MB-231 and MCF7 cells at a lower dosage than Erianin."( Ecust004 Suppresses Breast Cancer Cell Growth, Invasion, and Migration via EMT Regulation.
Hu, X; Huang, J; Huang, L; Liang, Y; Liu, Z; Nie, H; Sun, L; Wu, F, 2021)		0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)1.59000.25001.88388.7000AID214001; AID214002; AID214014; AID214033
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.91000.25001.87798.7000AID214001; AID214002; AID214033
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.91000.25001.86568.7000AID214001; AID214002; AID214033
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID1824704Induction of apoptosis in human HepG2 cells assessed as cell shrinkage at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824763Reversal of H2O2-induced cell death in human HCCLM3 cells at 10 nM pretreated for 24 hrs followed by H2O2 addition and further incubated for 24 hrs in presence of OAA by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824745Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on N-cadherin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824734Induction of apoptosis in human HCCLM3 cells assessed as decrease in cell viability at 20 to 40 nM incubated for 48 hrs in presence of 2 mM OAA MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214001Inhibition of glutamate-dependent tubulin polymerization at 30 degrees C(0.25 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824756Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of acetyl-CoA at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824760Inhibition of mitochondrial oxidative stress in PC knockout human HCCLM3 cells assessed as reduction in NADH/NAD ratio at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID103262Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824695Effect on cell cycle arrest in human HepG2 cells assessed as increase in accumulation of cells in G2/M phase at 20 to 80 nM incubated for 24 hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824717Induction of apoptosis in human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed as increase in total apoptotic cells in tumor at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by TUNEL staining based2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824727Binding affinity to recombinant pyruvate carboxylase (unknown origin) assessed as thermal stability at upto 1000 nM by cellular thermal transfer assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824731Inhibition of pyruvate carboxylase in human HCCLM3 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824755Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of serine at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824715Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 25 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 1.835 +/- 0.15 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824692Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824703Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as decrease in fibronectin expression level at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214163Inhibition of colchicine binding to tubulin isolated from bovine brain tissue1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID214159Concentration to inhibit 50% of tubulin polymerization from bovine brain1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
AID1824699Antimigratory activity in human HCCLM3 cells assessed as inhibition of scratch closure at 0.05 to 1 nM measured after 24 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824728Inhibition of pyruvate carboxylase in human HepG2 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824761Inhibition of mitochondrial oxidative stress in PC knockout human HCCLM3 cells assessed as reduction in GSH/GSSH ratio at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID84127Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824748Activation of AMPK pathway in human HCCLM3 cells assessed as increase in AMPK phosphorylation level at 5 nM measured after 1 hr by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824732Inhibition of pyruvate carboxylase in human HepG2 cells measured at 10 nM upto 24 hrs2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824697Effect on cell cycle arrest in human HepG2 cells assessed as increase accumulation of cells in G2/M phase at 20 nM measured upto 24 hrs hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824705Induction of apoptosis in human HepG2 cells assessed as cell rounding at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824708Induction of apoptosis in human HepG2 cells assessed as increase cleaved PARP level measured after 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824691Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824716Induction of apoptosis in human HepG2 cells xenografted in NCR-nu/nu mouse assessed as increase in total apoptotic cells in tumor at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by TUNEL staining based confoc2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420699Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824702Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as decrease in N-cadherin expression at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824712Antitumor activity against human HepG2 cells xenografted in NCR-nu/nu mouse assessed reduction in tumor growth at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214184Percentage inhibition of colchicine binding to tubulin by compound was evaluated1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Antineoplastic agents. 379. Synthesis of phenstatin phosphate.
AID1824706Induction of apoptosis in human HepG2 cells assessed as nuclear condensation at 100 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824689Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824701Inhibition of epithelial-mesenchymal transition in human HCCLM3 cells assessed as upregulation of E-cadherin expression at 0.05 to 1 nM incubated for 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824766Induction of glycolysis in PC knockout human HCCLM3 cells assessed as intracellular lactate concentration at 10 nM CheKine lactate assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824747Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on vimentin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824698Effect on cell cycle arrest in human HepG2 cells assessed as decrease in accumulation of cells at G0/G1 phase at 20 nM measured upto 24 hrs hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824694Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured upto 400 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824714Antitumor activity against human HepG2 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 0.92 +/- 0.13 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824730Inhibition of pyruvate carboxylase in human HepG2 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824741Antiproliferative activity against human SK-HEP1 cells transfected with PC-flag plasmid assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824737Induction of apoptosis in human HepG2 cells transfected with PC-flag plasmid assessed as reduction in cell viability at 20 to 100 nM incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824754Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of malate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824729Inhibition of pyruvate carboxylase in human HCCLM3 cells measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID98155Compound was tested for the inhibition of L1210 leukemia cells growth in mice1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824733Inhibition of pyruvate carboxylase in human HepG2 cells measured at 0.001 to 10 nM for 24 hrs2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824767Induction of apoptosis in human HCCLM3 cells assessed as cell rounding at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824693Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth at 10 to 200 nM measured up to 3 days by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824768Induction of apoptosis in human HCCLM3 cells assessed as cell shrinkage at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824723Cytotoxicity against human HepG2 cells assessed as cell viability at 62.5 to 250 nM preincubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824738Induction of apoptosis in human HCCLM3 cells transfected with PC-flag plasmid assessed as reduction in cell viability at 20 to 100 nM incubated for 24 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214171Effect on the binding of radiolabeled [3H]colchicine to tubulin1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824770Induction of apoptosis in human HCCLM3 cells assessed as nuclear condensation at 20 nM incubated for 24 hrs by DAPI staining based phase contrast microscopic analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824744Inhibition of epithelial transition in human SK-HEP1 cells overexpressing PC assessed as effect on E-cadherin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824690Antiproliferative activity against human MHCC97 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824721Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in lung at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824740Anti-invasive activity against PC knockout human HCCLM3 cells assessed as suppression of cell invasion at 0.05 nM measured after 48 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID9208Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID214176Inhibition of colchicine binding to tubulin was evaluated only when polymerization IC50 <=1.0 uM1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID1824711Toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as effect on body weight at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured every three days2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214014Inhibition of tubulin polymerization1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1824718Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in heart at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824710Toxicity in NCR-nu/nu mouse bearing human HepG2 tumor assessed as effect on body weight at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured every three days2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824722Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in kidney at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824753Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of oxaloacetate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824749Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of fumarate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824759Induction of mitochondrial oxidative stress in human HCCLM3 cells overexpressing PC assessed as accumulation of ROS at 10 nM by DCFH-DA staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824769Antiinvasive activity against human HCCLM3 cells assessed as reduction in cell invasion at 0.05 to 1 nM by matrigel transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID152759Concentration required for 50% inhibition of P388 murine leukemia cell growth in MTT assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers.
AID1824709Induction of caspase-mediated apoptosis in human HepG2 cells assessed as reduction in cell viability at 100 to 400 nM incubated for 48 hrs in presence of Z-VAD-FMK by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824719Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in liver at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824765Induction of glycolysis in PC knockout human HCCLM3 cells assessed as intracellular glucose consumption at 10 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824707Induction of apoptosis in human HepG2 cells assessed as activation of caspase 3 measured after 24 hrs by Western blot analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824752Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of ATP at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824726Competitive inhibition of recombinant pyruvate carboxylase in human HepG2 cell lysate in presence of Erianin at 20 uM for 120 mins followed by irradiation of 365 nm UV light for 15 min by Native -PAGE analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1256166Inhibition of Quorum sensing system in Chromobacterium violaceum CV026 after 24 hrs by agar-well diffusion method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1824762Cytotoxicity against human HCCLM3 cells assessed as reduction in cell viability at 5 to 20 nM incubated for 48 hrs in presence of H2O2 by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID42665Ability to inhibit Tubulin polymerization in Bovine brain1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID420701Displacement of [3H]colchicine from bovine brain tubulin at 5 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID82183Cytotoxicity of compound against HL-60 human leukemia cells1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID214166Inhibition of radiolabeled Colchicine binding to tubulin at 30 degrees C (0.25 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824758Induction of mitochondrial oxidative stress in human HCCLM3 cells assessed as accumulation of ROS at 10 nM by DCFH-DA staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824720Systemic toxicity in NCR-nu/nu mouse bearing human HCCLM3 tumor assessed as pathological change in spleen at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation by H and E staining based analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214002Concentration required to inhibit the extent of glutamate-dependent tubulin polymerization by 50% at 37 degrees C(1.0 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824771Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed wet tumor weight at 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation (Rvb= 1.835 +/- 0.15 g)2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420700Displacement of [3H]colchicine from bovine brain tubulin at 1 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824751Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of L-lactate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824700Antimigratory activity in human HCCLM3 cells assessed as inhibition of scratch closure at 0.05 to 1 nM measured after 24 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824757Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of aspartate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824739Antimigratory activity against PC knockout human HCCLM3 cells assessed as suppression of cell migration at 0.5 nM measured after 48 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID202827Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID106876Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1824736Cytotoxicity against PC knockout human HCCLM3 cells assessed as reduction in cell viability at 20 to 100 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824742Antimigratory activity in human SK-HEP1 cells overexpressing PC assessed as suppression of cell migration at 0.5 nM measured after 48 hrs by wound healing assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214167Inhibition of radiolabeled Colchicine binding to tubulin at 37 degrees C (1.0 mM MgCl2)1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
AID1824746Inhibition of mesenchymal transition in human SK-HEP1 cells overexpressing PC assessed as effect on fibronectin expression2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824713Antitumor activity against human HCCLM3 cells xenografted in NCR-nu/nu mouse assessed reduction in tumor growth at 25 to 50 mg/kg, ip administered alternate days for 21 days and measured 26 days post implantation2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID214033Inhibition of bovine tubulin polymerization1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID1824750Induction of glycolysis in human HCCLM3 cells assessed as decrease in level of succinate at 5 nM2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824764Effect on ATP production in PC knockout human HCCLM3 cells assessed as reduction in intracellular ATP level at 10 nM by CellTiter-Lumni plus cell viability assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824735Cytotoxicity against PC knockout human HepG2 cells assessed as reduction in cell viability at 20 to 100 nM measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824696Effect on cell cycle arrest in human HepG2 cells assessed as decrease in accumulation of cells at G0/G1 phase incubated for 24 hrs by propidium iodide staining based flow cytometry analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID420703Inhibition of bovine brain tubulin by spectrophotometry2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID1824743Anti-invasive activity in human SK-HEP1 cells overexpressing PC assessed as suppression of cell invasion at 0.05 nM measured after 48 hrs by transwell assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (9.26)18.2507
2000's5 (9.26)29.6817
2010's12 (22.22)24.3611
2020's32 (59.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.45 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzene
[no description available]		2.0710aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
naphthalene
[no description available]		7.0710naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
oxaloacetic acid
Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.. oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group.		2.4110C4-dicarboxylic acid;
oxo dicarboxylic acid		geroprotector;
metabolite
phenol
[no description available]		6.25380phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.4110aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
2,3,4,6-tetrachlorophenol
2,3,4,6-tetrachlorophenol: RN given refers to parent cpd; see also record for tetrachlorophenol with locants for chloro groups not specified. 2,3,4,6-tetrachlorophenol : A tetrachlorophenol in which the chlorines are located at positions 2, 3, 4, and 6.		2.0710tetrachlorophenolxenobiotic metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.3920alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
scoparone
scoparone: structure. scoparone : A member of the class of coumarins that is esculetin in which the two hydroxy groups at positions 6 and 7 are replaced by methoxy groups. It is a major constituent of the Chinese herbal medicine Yin Chen Hao, and exhibits a variety of pharmacological activities such as anti-inflammatory, anti-allergic, and anti-tumor activities.		2.2510aromatic ether;
coumarins		anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.6730furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
thiocholchicine
thiocholchicine: RN refers to (S)-isomer		2.3820
ruthenium
Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.		7.610iron group element atom;
platinum group metal atom
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.610diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
octyl gallate
[no description available]		2.4110gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
1,7-phenanthroline
[no description available]		2.610phenanthroline
combretastatin
combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN		2.3110
dendrophenol
dendrophenol: isolated from Dendrobium loddigesii		2.7220
(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone: a tubulin inhibitor with antineoplastic activity; structure in first source		2.0510
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.2510(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
Hircinol
[no description available]		2.4110phenanthrenes
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.1110resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
rhapontin
rhapontin: constituent of rhubarb rhizome		2.4110rhaponticinangiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite
3,3',4,5'-tetrahydroxystilbene
3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.		2.1110catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
gigantol
gigantol: structure in first source		2.4110
trans-2,3',4,5'-tetrahydroxystilbene
trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol		2.1110stilbenoid
pterostilbene
[no description available]		2.1110diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
fosbretabulin
[no description available]		3.2460stilbenoid
3,3',4,5'-tetramethoxy-trans-stilbene
(E)-3,4,3',5'-tetramethoxystilbene: from the leaves of Eugenia rigida; structure in first source		1.9710
dmu-212
[no description available]		2.4120
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
[no description available]		2.3920
combretastatin a-4 disodium phosphate
[no description available]		1.9910
gentamicin sulfate
[no description available]		2.1110
bibw 2992
[no description available]		2.4110aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
cyclic diadenosine phosphate
cyclic di-AMP : A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of AMP.		2.4110adenyl ribonucleotide;
cyclic purine dinucleotide		Mycoplasma genitalium metabolite
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.2110
complestatin
complestatin: compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding. isocomplestatin : A heterodetic cyclic peptide which is a atropisomer of complestatin. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity.. chloropeptin II : A heterodetic cyclic peptide consisting of N-acylated trytophan, 3,5-dichloro-4-hydroxyphenylglycine, 4-hydroxyphenylglycine, 3,5-dichloro-4-hydroxyphenylglycyl, tyrosine and 4-hydroxyphenylglycine residues joined in sequence and in which the side-chain of the central 4-hydroxyphenylglycine residue is attached to the side-chain of the tryptophan via a C3-C6 bond and to the side-chain of the tyrosine via an ether bond from C5. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity.		2.0710cyclic ether;
heterodetic cyclic peptide;
indoles;
organic heterobicyclic compound;
organochlorine compound;
peptide antibiotic;
polyphenol		anti-HIV-1 agent;
antimicrobial agent;
HIV-1 integrase inhibitor;
metabolite
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.2510benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9810
Breast Cancer
[description not available]		07.9540
Cancer of Colon
[description not available]		02.730
Cancer of Lung
[description not available]		02.730
Malignant Melanoma
[description not available]		02.7230
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9540
Colonic Neoplasms
Tumors or cancer of the COLON.		02.730
Lung Neoplasms
Tumors or cancer of the LUNG.		02.730
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.7230
Carcinoma, Oat Cell
[description not available]		01.9810
Leucocythaemia
[description not available]		01.9810
Central Nervous System Neoplasm
[description not available]		01.9810
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9810
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		01.9810
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9810
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9910
Hepatocellular Carcinoma
[description not available]		03.4460
Cancer of Liver
[description not available]		03.5870
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		03.4460
Liver Neoplasms
Tumors or cancer of the LIVER.		03.5870
Diabetes Mellitus, Adult-Onset
[description not available]		02.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.7620
Primary Peritonitis
[description not available]		02.3110
Gouty Arthritis
[description not available]		02.3110
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.3110
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.3110
Arthritis, Gouty
Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular. Acute and chronic gouty arthritis are associated with accumulation of MONOSODIUM URATE in and around affected joints.		02.3110
Neovascularization, Optic Disc
[description not available]		02.4110
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.4110
Angiogenesis, Pathologic
[description not available]		02.9430
Palmoplantaris Pustulosis
[description not available]		02.4110
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		07.4110
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		07.610
Colorectal Cancer
[description not available]		08.1130
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		03.1130
Fatty Liver, Nonalcoholic
[description not available]		02.610
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.610
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		07.610
Cancer of Esophagus
[description not available]		02.610
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.610
Bone Cancer
[description not available]		03.5210
Cancer of Nasopharynx
[description not available]		03.6420
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		03.5210
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		03.6420
Carcinoma, Epidermoid
[description not available]		02.2510
Cancer of Mouth
[description not available]		02.2510
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.2510
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.2510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.2510
Cancer of Skin
[description not available]		02.4820
Skin Neoplasms
Tumors or cancer of the SKIN.		02.4820
Colitis Gravis
[description not available]		02.2510
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		02.2510
Invasiveness, Neoplasm
[description not available]		02.9130
Experimental Neoplasms
[description not available]		02.2510
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.2510
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.3110
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.3110
Condition, Preneoplastic
[description not available]		02.3110
Cancer of Stomach
[description not available]		02.3110
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.3110
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.3110
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		07.2110
Bladder Cancer
[description not available]		07.2110
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.2110
Osteogenic Sarcoma
[description not available]		02.1310
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.1310
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.1510
Innate Inflammatory Response
[description not available]		02.1510
Metastase
[description not available]		02.1510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1510
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.1510
Benign Neoplasms
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610